Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:80521
Name lung non-squamous non-small cell carcinoma
Definition A lung non-small cell carcinoma that is characterized by the lack of evidence of squamous differentiation.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer respiratory system cancer lung cancer lung carcinoma lung non-small cell carcinoma lung non-squamous non-small cell carcinoma

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Unknown unknown Itraconazole + Pemetrexed Disodium lung non-squamous non-small cell carcinoma not applicable detail...
Unknown unknown Motesanib Diphosphate + Paclitaxel lung non-squamous non-small cell carcinoma not applicable detail...
Unknown unknown Carboplatin + Motesanib Diphosphate lung non-squamous non-small cell carcinoma not applicable detail...
Unknown unknown Carboplatin + Linifanib + Paclitaxel lung non-squamous non-small cell carcinoma not applicable detail...
Unknown unknown Carboplatin + Demcizumab + Pemetrexed Disodium lung non-squamous non-small cell carcinoma not applicable detail...
Unknown unknown Bevacizumab-awwb + Carboplatin + Paclitaxel lung non-squamous non-small cell carcinoma not applicable detail...
Unknown unknown Carboplatin + Motesanib Diphosphate + Paclitaxel lung non-squamous non-small cell carcinoma no benefit detail...
Unknown unknown Cisplatin + LY2603618 + Pemetrexed Disodium lung non-squamous non-small cell carcinoma no benefit detail...
ALK rearrange Ceritinib lung non-squamous non-small cell carcinoma sensitive detail...
Unknown unknown Bavituximab + Docetaxel lung non-squamous non-small cell carcinoma no benefit detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT01631279 Phase Ib/II TH-4000 A Dose Escalation Trial of PR610 Treating Patients With Solid Tumors Terminated
NCT02657434 Phase III Cisplatin + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium Atezolizumab + Carboplatin + Pemetrexed Disodium Atezolizumab + Cisplatin + Pemetrexed Disodium A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower 132) Active, not recruiting
NCT02810457 Phase III Carboplatin + FKB238 + Paclitaxel Bevacizumab + Carboplatin + Paclitaxel Evaluation of FKB238 and Avastin in Patients With Advanced/Recurrent Non-squamous Non-small Cell Lung Cancer (AVANA) Active, not recruiting
NCT03449381 Phase I BI 907828 This Study Aims to Find the Best Dose of BI 907828 in Patients With Different Types of Advanced Cancer (Solid Tumors) Recruiting
NCT03468426 Phase I BI 754091 + BI 836880 A Study to Test Different Doses of BI 836880 Combined With BI 754091 in Patients With Advanced Non-small Cell Lung Cancer Followed by Other Types of Advanced Solid Tumours Recruiting
NCT03752398 Phase I XmAb23104 A Study of XmAb23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) (DUET-3) Recruiting
NCT03786692 Phase II Atezolizumab + Bevacizumab + Carboplatin + Pemetrexed Disodium Bevacizumab + Carboplatin + Pemetrexed Disodium Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC Recruiting
NCT03909334 Phase II Osimertinib + Ramucirumab Osimertinib Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Recruiting
NCT03976323 Phase III Pembrolizumab + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium Olaparib + Pembrolizumab Cisplatin + Pembrolizumab + Pemetrexed Disodium Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006) Recruiting
NCT03976375 Phase III Lenvatinib Lenvatinib + Pembrolizumab Docetaxel Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008) Recruiting
NCT04027946 Phase II LMB-100 + Pembrolizumab LMB-100 Followed by Pembrolizumab in the Treatment of Adults With Mesothelin-Expressing Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Recruiting
NCT04035486 Phase III Osimertinib Carboplatin + Osimertinib + Pemetrexed Disodium Cisplatin + Osimertinib + Pemetrexed Disodium Osimertinib + Pemetrexed Disodium A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2) (FLAURA2) Recruiting
NCT04043195 Phase Ib/II Ipilimumab + Nivolumab + Oxaliplatin Nivolumab + Oxaliplatin Nivolumab and Ipilimumab in Combination With Immunogenic Chemotherapy for Patients With Advanced NSCLC (NSCLC) Recruiting
NCT04084717 Phase II Crizotinib Study of Crizotinib for ROS1 and MET Activated Lung Cancer Not yet recruiting
NCT04093167 Phase II Pembrolizumab Study of Molecular Response Adaptive Immuno-Chemotherapy in Patients With NSCLC Recruiting
NCT04099836 Phase II Atezolizumab + Bevacizumab Atezolizumab and Bevacizumab in Epidermal Growth Factor Receptor (EGFR) Mutant Non?Small Cell Lung Cancer in Patients With Progressive Disease After Receiving Osimertinib Recruiting
NCT04112498 Phase I Nivolumab + Relatlimab + rHuPH20 A Phase 1, Bioavailability Study of Relatlimab in Combination With Nivolumab Recruiting
NCT04154956 Phase III SAR408701 Docetaxel SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small Cell Lung Cancer Patients (CARMEN-LC03) Recruiting
NCT04163432 Phase II Carboplatin + Durvalumab + Pemetrexed Disodium Durvalumab + Pemetrexed Disodium Staggered, Chemo-Immunotherapy With Durvalumab, MEDI4736 Pemetrexed & Carboplatin (PC) for Metastatic Non-Squamous NSCLC (STAGGER) Recruiting
NCT04173507 Phase II Avelumab + Talazoparib Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial) Recruiting
NCT04194944 Phase III Cisplatin + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium Selpercatinib Carboplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer (LIBRETTO-431) Recruiting
NCT04225117 Phase II Enfortumab vedotin-ejfv A Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) Recruiting
NCT04262856 Phase II AB154 + AB928 + GLS-010 GLS-010 AB154 + GLS-010 Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer (ARC-7) Recruiting
NCT04265534 Phase II Carboplatin + Dexamethasone + Pembrolizumab + Pemetrexed Disodium + Telaglenastat Carboplatin + Dexamethasone + Pembrolizumab + Pemetrexed Disodium KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC (KEAPSAKE) Recruiting
NCT04310007 Phase II Nab-paclitaxel Gemcitabine Cabozantinib + Nivolumab Cabozantinib Docetaxel Paclitaxel Docetaxel + Ramucirumab Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer Recruiting
NCT04332367 Phase II Carboplatin + Paclitaxel + Ramucirumab Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance Recruiting
NCT04381650 Phase Ib/II Pembrolizumab + TAK-981 A Safety and Efficacy Study of TAK-981 Plus Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors Recruiting
NCT04432857 Phase I E7046 + Pembrolizumab AN0025 and Pembrolizumab Combination in Advanced Solid Tumors Recruiting
NCT04434560 Phase II Ipilimumab + Nivolumab Neoadjuvant Immunotherapy in Brain Metastases Not yet recruiting